Federal Register / Vol. 71, No. 218 / Monday, November 13, 2006 / Notices 66181 

Agenda: To review and evaluate grant 

applications. 

Place: The Melrose Hotel, 2430 

Pennsylvania Avenue, NW., Washington, DC 

20037. 

Contact Person: Richard J. Bartlett, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4110, 

MSC 7814, Bethesda, MD 20892, 301–435–

6809, bartletr@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, AIDS 

Clinical Studies and Epidemiology. 

Date: November 17, 2006. 

Time: 11 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Ranga V. Srinivas, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5222, 

MSC 7852, Bethesda, MD 20892, (301) 435–

1167, srinivar@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflict: Musculoskeletal Rehabilitation. 

Date: November 21, 2006. 

Time: 10 a.m. to 11:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Daniel F. McDonald, PhD, 

Scientific Review Administrator, Chief, 

MOSS IRG, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 4214, MSC 7814, Bethesda, MD 

20892, (301) 435–1215, 

mcdonald@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflict: Musculoskeletal Tissue 

Engineering. 

Date: November 21, 2006. 

Time: 4:30 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Daniel F. McDonald, PhD, 

Scientific Review Administrator, Chief, 

MOSS IRG, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 4214, MSC 7814, Bethesda, MD 

20892, (301) 435–1215, 

mcdonald@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Fogarty 

International Brain Disorders Meeting. 

Date: November 27–28, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Latham Hotel, 3000 M Street, NW., 

Washington, DC 20007. 

Contact Person: Dan D. Gerendasy, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5132, 

MSC 7843, Bethesda, MD 20892, (301) 594–

6830, gerendad@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflicts in Biological Chemistry and 

Macromolecular Biophysics. 

Date: November 27, 2006. 

Time: 3 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Donald L. Schneider, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4172, 

MSC 7806, Bethesda, MD 20892, (301) 435–

1727, schneidd@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, AIDS 

Epidemiology and Clinical Studies. 

Date: November 28, 2006. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Ranga V. Srinivas, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5222, 

MSC 7852, Bethesda, MD 20892, (301) 435–

1167, srinivar@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Opportunistic Malignancies in AIDS. 

Date: November 29, 2006. 

Time: 10 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Mary Clare Walker, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5208, 

MSC 7852, Bethesda, MD 20892, (301) 435–

1165, walkermc@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, ACTS 

Member Conflicts Special Emphasis Panel. 

Date: November 30, 2006. 

Time: 8:30 a.m. to 10 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: William F. Bolger Center, Dolce 

International, 9600 Newbridge Drive, 

Potomac, MD 20854. 

Contact Person: Richard J. Bartlett, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4110, 

MSC 7814, Bethesda, MD 20892, (301) 435–

6809, bartletr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, ACTS SBIR/ 

STTR Special Emphasis Panel. 

Date: November 30, 2006. 

Time: 10:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: William F. Bolger Center, Dolce 

International, 9600 Newbridge Drive, 

Potomac, MD 20854. 

Contact Person: Richard J. Bartlett, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4110, 

MSC 7814, Bethesda, MD 20892, (301) 435–

6809, bartletr@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.892, 93.893, National Institutes of 

Health, HHS) 

Dated: November 2, 2006. 

Anna Snuffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9156 Filed 11–9–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Institutes of Health Peer 

Review Advisory Committee. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Institutes of 

Health Peer Review Advisory Committee. 

Date: December 4, 2006. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: Provide technical and scientific 

advice to the Director, National Institutes of 

Health (NIH), the Deputy Director for 

Extramural Research, NIH and the Director, 

Center for Scientific Review (CSR), on 

matters relating broadly to review procedures 

and policies for the evaluation of scientific 

and technical merit of applications for grants 

and awards. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, Rooms 

E1–E2, Bethesda, MD 20892. 

Contact Person: Cheryl A. Kitt, PhD, 

Executive Secretary, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 3030, MSC 7776, 

Bethesda, MD 20892, 301–435–1112, 

kittc@csr.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 


cprice-sewell on PROD1PC66 with NOTICES
66182 Federal Register / Vol. 71, No. 218 / Monday, November 13, 2006 / Notices 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844; 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: November 6, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9171 Filed 11–9–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Field of Use: Treatment of 

Inflammatory Diseases Using Ghrelin 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of an exclusive 

license to practice the invention 

embodied in: 

U.S. Provisional Patent application, 

S/N 60/569,819 filed May 11, 2004, 

entitled ‘‘Methods for Inhibiting 

Proinflammatory Cytokine Expression 

Using Ghrelin,’’ converted to PCT on 

May 11, 2005 (E–016–2004/0–PCT–02), 

(Inventors: Vishwa D. Dixit, Dennis D. 

Taub, Eric Schaffer, and Dzung Nguyen) 

(NIA), to Sapphire Therapeutics, Inc. 

(Hereafter Sapphire), having a place of 

business in Bridgewater of NJ. The 

patent rights in these inventions have 

been assigned to the United States of 

America. 

DATES: Only written comments and/or 

application for a license, which are 

received by the NIH Office of 

Technology Transfer on or before 

January 12, 2007 will be considered. 

ADDRESSES: Requests for a copy of the 

patent application, inquiries, comments 

and other materials relating to the 

contemplated license should be directed 

to: Sally Hu, PhD, M.B.A., Office of 

Technology Transfer, National Institutes 

of Health, 6011 Executive Boulevard, 

Suite 325, Rockville, MD 20852–3804; email: hus@od.nih.gov; telephone: (301) 

435–5606; facsimile: (301) 402–0220. 

SUPPLEMENTARY INFORMATION: The 

prospective exclusive license will be 

royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 60 days from the date of this 

published Notice, NIH receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404.7. 

E–016–2004/0–US–01 provides 

methods for treating inflammation by 

inhibiting pro-inflammatory cytokine 

expression using Ghrelin, or a fragment 

thereof. Inflammation could be caused 

by a variety of viral, bacterial, fungal, or 

parasitic infections. The invention also 

provides methods for treating loss of 

appetite, and sepsis. Ghrelin, a naturally 

occurring peptide hormone was shown 

to be the ligand for growth hormone 

secretagogue receptor (GHS–R ), and is 

mainly produced by the epithelial cells 

in the stomach. Ghrelin exerts many 

important actions in the body, including 

stimulation of growth hormone 

secretion, induction of appetite, and 

regulation of energy expenditure. 

Ghrelin directly controls human growth 

hormone and insulin growth factor 

expression by human immune cells. The 

inventors showed that Ghrelin exerts 

anti-inflammatory effects by inhibiting 

the secretion of acute and chronic 

cytokines, including IL–1, IL–6, TNF–a, 

IFN–g, IL–12, chemokines, and CSF in 

vitro and in in vivo mouse models of 

sepsis and inflammation. This invention 

can be useful for treatment of various 

inflammatory disorders, including 

inflammatory bowel disease, Crohn’s 

disease, rheumatoid arthritis, multiple 

sclerosis, atherosclerosis, endotoxemia, 

and graft-versus-host disease. It can also 

be used as a treatment for loss of 

appetite and sepsis. 

The field of use may be limited to the 

use of Ghrelin as a novel drug to treat 

a range of inflammatory diseases. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: October 30, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E6–19051 Filed 11–9–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Bureau of Customs and Border 

Protection 

Notice of Intent To Prepare a Draft 

Environmental Impact Statement for 

Department of Homeland Security, 

Customs and Border Protection, Office 

of Border Patrol, Laredo Sector, 

Laredo North and South Station’s 

Road Improvement and Non-Native 

Vegetation Removal Project 

AGENCY: U.S. Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: Notice of Intent to Prepare a 

Draft Environmental Impact Statement 

(DEIS). 

SUMMARY: The U.S. Army Corps of 

Engineers on behalf of the U.S. Customs 

and Border Protection (CBP) will 

prepare a Draft Environmental Impact 

Statement pursuant to the National 

Environmental Policy Act of 1969 

(NEPA) for the construction and 

improvement of existing patrol roads 

and the removal of non-native (giant 

cane, Arundo donax) vegetation along 

111 miles of the Rio Grande (Proposed 

Action) in Webb County, Texas. The 

U.S. Customs and Border Protection is 

the decision-making agency for this 

project. This EIS is being prepared in 

support of the proposal by the Office of 

Border Patrol’s (OBP) Laredo North and 

Laredo South Stations for controlling 

and deterring the influx of illegal 

immigration and contraband into the 

United States. Due to the increased 

violent activity in Nuevo Laredo, 

Mexico and increase in drug trafficking 

in Webb County, the Secretary of 

Homeland Security has mandated this 

effort as the top priority of the OBP’s 

Laredo Sector. 

The Laredo Sector has a need to 

secure the border by obtaining an 

unobstructed line of sight to the Rio 

Grande and a continuous patrol road. 

These actions are intended to gain and 

maintain control of the border to further 

prevent the influx of illegal aliens and 

drugs into the United States. 


cprice-sewell on PROD1PC66 with NOTICES